Executive Profile*

James S. Turley

AgeTotal Calculated CompensationThis person is connected to 205 board members in 6 different organizations across 9 different industries.

See Board Relationships


Mr. James S. Turley, also known as Jim, serves as the Chairman of the National Corporate Theatre Fund. Mr. Turley has been an Independent Director of Northrop Grumman Corporation since February 19, 2015. He has been a Director of Citigroup Inc. since July 2013 and has been an Independent Director of Emerson Electric Co. since July 10, 2013. He has been an Independent Director of Intrexon Corporation since April 16, 2014. Mr. Turley serves on President Obama's Export ...

Read Full Background

Corporate Headquarters*

5 Times Square
New York, New York 10036-6530

United States

Phone: 212-773-3000
Fax: 212-773-6350

Board Members Memberships*

Independent Director
Independent Director and Chairman of Compensation Committee
Independent Director


Bachelor's Degree
Rice University
Master's Degree
Rice University

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

Exercisable Options41,403
Exercisable Options Value$289,822
Unexercisable Options31,053
Unexercisable Options Value$347,794
Total Value of Options$637,616
Total Number of Options72,456

Total Compensation*

Total Annual Cash Compensation$59,967
Total Calculated Compensation$459,563
*Data is at least as current as the most recent Definitive Proxy.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup


Nick Leschly Chief Executive Officer, President and Director
bluebird bio, Inc.
André Choulika Ph.D.Co-Founder, Chairman and Chief Executive Officer
Cellectis S.A.
James Julian Noble M.A., F.C.A.Chief Executive Officer and Director
Adaptimmune Therapeutics plc
460.0K GBP
Arie S. Belldegrun M.D., FACSFounder, Executive Chairman, Chief Executive Officer and President
Kite Pharma, Inc.
Hans E. Bishop Co-Founder, Chief Executive Officer, President and Director
Juno Therapeutics, Inc.
Compensation as of Fiscal Year 2015.

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.